Senseonics and Sequel collaborate to implement long-term glucose monitor in an autonomous insulin delivery system
In a significant stride for diabetes care, Senseonics and Sequel Med Tech are set to launch an integrated Automated Insulin Delivery (AID) system in the third quarter of 2025. This system promises to revolutionise diabetes management by combining Senseonics' Eversense 365 Continuous Glucose Monitoring (CGM) system with Sequel's Twiist insulin delivery device.
The Twiist system will be compatible with Senseonics' Eversense 365 CGM, which received FDA Interoperable CGM (iCGM) clearance in September 2024. This integration offers users a long-duration sensor integrated with insulin delivery, enhancing diabetes management.
In addition, Sequel's Twiist system will support Abbott’s FreeStyle Libre 3 Plus sensor, providing users greater flexibility in choosing glucose sensors.
Senseonics has reported substantial growth in its global patient base, increasing by 56% to about 6,000 patients, attributed in part to the launch of Eversense 365 in the U.S. This strong market acceptance bodes well for the integrated system’s uptake.
Revenue for Q4 2024 reached $8.3 million, with full-year 2024 revenue at $22.5 million, despite a net loss. Commercialising the integrated AID system is expected to contribute to revenue growth and improved market penetration.
Mukul Jain, Senseonics COO, stated that the team has passed prototyping with potential pump partners in a couple of instances. He expressed hope for public discussions about integrations with pump partners in the coming quarters.
The partnership signifies a significant advance in diabetes care by combining the benefits of a long-term CGM sensor with automated insulin dosing. This integration is expected to improve glucose control, convenience, and personalisation for type 1 diabetes patients.
Sequel is the first insulin pump firm to work with Senseonics, marking a milestone in the collaboration. No new information about specific pump partnerships or launch dates was provided. However, Jain emphasized the importance of compatibility with various CGM and pump systems due to patient preferences for changes.
In summary, the partnership between Senseonics and Sequel Med Tech is poised to positively impact Senseonics’ commercial growth by expanding its patient base and offering innovations in diabetes treatment technology. The planned launch of the system in Q3 2025 aims to deliver enhanced diabetes management through the novel combination of a one-year CGM and automated insulin delivery.
- The FDA has granted Interoperable CGM (iCGM) clearance to Senseonics' Eversense 365 Continuous Glucose Monitoring (CGM) system, which will be integrated with Sequel's Twiist insulin delivery device.
- Senseonics' revenue for Q4 2024 reached $8.3 million, with full-year 2024 revenue at $22.5 million, indicating substantial growth in the global patient base, which increased by 56% to about 6,000 patients.
- The collaboration between Senseonics and Sequel Med Tech signifies a significant advance in diabetes care, combining the benefits of a long-term CGM sensor with automated insulin dosing.
- Mukul Jain, Senseonics COO, stated that the team has passed prototyping with potential pump partners in a couple of instances and emphasized the importance of compatibility with various CGM and pump systems due to patient preferences for changes.
- The integration between Senseonics' Eversense 365 CGM and Sequel's Twiist insulin delivery device offers users a long-duration sensor integrated with insulin delivery, enhancing diabetes management.
- sequel's Twiist system will support Abbott’s FreeStyle Libre 3 Plus sensor, providing users greater flexibility in choosing glucose sensors while using the integrated Automated Insulin Delivery (AID) system.
